125 related articles for article (PubMed ID: 38131101)
1. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab.
Sánchez LM; George A; Friend BD; Bhar S; Sasa G; Doherty EE; Craddock J; Steffin D; Salem B; Yassine K; Omer B; Martinez C; Leung K; Krance RA; John TD
Pediatr Hematol Oncol; 2024 May; 41(4):260-272. PubMed ID: 38131101
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
3. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Kharbanda S; Smith AR; Hutchinson SK; McKenna DH; Ball JB; Lamb LS; Agarwal R; Weinberg KI; Wagner JE
Biol Blood Marrow Transplant; 2014 Apr; 20(4):581-6. PubMed ID: 24370862
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
5. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Khandelwal P; Yeh RF; Yu L; Lane A; Dandoy CE; El-Bietar J; Davies SM; Grimley MS
Transplantation; 2021 Apr; 105(4):891-896. PubMed ID: 32467478
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
[TBL] [Abstract][Full Text] [Related]
11. Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial.
Shenoy S; Walters MC; Ngwube A; Soni S; Jacobsohn D; Chaudhury S; Grimley M; Chan K; Haight A; Kasow KA; Parikh S; Andreansky M; Connelly J; Delgado D; Godder K; Hale G; Nieder M; Pulsipher MA; Trachtenberg F; Neufeld E; Kwiatkowski JL; Thompson AA
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1216-1222. PubMed ID: 29374585
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.
Marsh JC; Gupta V; Lim Z; Ho AY; Ireland RM; Hayden J; Potter V; Koh MB; Islam MS; Russell N; Marks DI; Mufti GJ; Pagliuca A
Blood; 2011 Aug; 118(8):2351-7. PubMed ID: 21518925
[TBL] [Abstract][Full Text] [Related]
13. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
[TBL] [Abstract][Full Text] [Related]
15. Total body irradiation-free haploidentical peripheral blood stem cell transplantation compared to related and unrelated donor transplantation in pediatrics with acute lymphoblastic leukemia.
Mardani M; Behfar M; Jafari L; Mohseni R; Naji P; Salajegheh P; Donyadideh G; Hamidieh AA
Pediatr Blood Cancer; 2023 May; 70(5):e30255. PubMed ID: 36815626
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor αβ
Shah RM; Elfeky R; Nademi Z; Qasim W; Amrolia P; Chiesa R; Rao K; Lucchini G; Silva JMF; Worth A; Barge D; Ryan D; Conn J; Cant AJ; Skinner R; Abd Hamid IJ; Flood T; Abinun M; Hambleton S; Gennery AR; Veys P; Slatter M
J Allergy Clin Immunol; 2018 Apr; 141(4):1417-1426.e1. PubMed ID: 28780238
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3
Lum SH; James B; Ottaviano G; Ewins AM; Patrick K; Ali S; Carpenter B; Silva J; Tewari S; Furness C; Thomas A; Shenton G; Bonney D; Moppett J; Hambleton S; Gennery AR; Amrolia P; Gibson B; Hough R; Rao K; Slatter M; Wynn R
Transplant Cell Ther; 2024 Mar; 30(3):314.e1-314.e12. PubMed ID: 38103787
[TBL] [Abstract][Full Text] [Related]
18. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.
Marsh JC; Pearce RM; Koh MB; Lim Z; Pagliuca A; Mufti GJ; Perry J; Snowden JA; Vora AJ; Wynn RT; Russell N; Gibson B; Gilleece M; Milligan D; Veys P; Samarasinghe S; McMullin M; Kirkland K; Cook G;
Bone Marrow Transplant; 2014 Jan; 49(1):42-8. PubMed ID: 23912664
[TBL] [Abstract][Full Text] [Related]
20. Effect of allogeneic hematopoietic stem cell transplantation for chronic granulomatous disease in children: A multicentre, retrospective cohort study in China.
Si Y; Dou Y; Zhai X; Zhou C; Lu W; Meng Y; Qian X; Chen J; Wang P; Luo C; Yu J; Tang X
Clin Immunol; 2024 Mar; 260():109919. PubMed ID: 38309448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
